Accessibility Menu
MindMaze Therapeutics logo

MindMaze Therapeutics

(OTC) RLFTF

Current Price$0.29
Market Cap$53.22M
Since IPO (2025)-86%
5 Year-100%
1 Year-88%
1 Month-37%

MindMaze Therapeutics Financials at a Glance

Market Cap

$53.22M

Revenue (TTM)

CHF 12.65M

Net Income (TTM)

-CHF 63.28M

EPS (TTM)

-$1.56

P/E Ratio

-0.21

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$0.29

Volume

6,998

Open

$0.27

Previous Close

$0.33

Daily Range

$0.27 - $0.33

52-Week Range

$0.27 - $4.88

Estimated Earnings Date

Apr 8, 2026

RLFTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MindMaze Therapeutics

Industry

Biotechnology

Employees

31

CEO

Alexandre Capet

Headquarters

Lausanne, 1202, CH

RLFTF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-41%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-4.76%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$53.22M

Shares Outstanding

159.10M

Volume

7.00K

Avg. Volume

3.91K

Financials (TTM)

Gross Profit

CHF 5.84M

Operating Income

-CHF 18.89M

EBITDA

-CHF 16.58M

Operating Cash Flow

-CHF 2.92M

Capital Expenditure

-CHF 172.00K

Free Cash Flow

-CHF 3.09M

Cash & ST Invst.

CHF 15.08M

Total Debt

CHF 2.14M

MindMaze Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

CHF 1.22M

-59.7%

Gross Profit

CHF 619.00K

+110.8%

Gross Margin

50.82%

N/A

Market Cap

$53.22M

N/A

Market Cap/Employee

$1.72M

N/A

Employees

31

N/A

Net Income

-CHF 4.48M

+92.1%

EBITDA

-CHF 4.02M

+20.6%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

CHF 12.50M

-2.3%

Total Debt

CHF 1.90M

-41.3%

Accounts Receivable

CHF 1.47M

-29.0%

Inventory

CHF 923.00K

+105.1%

Long Term Debt

CHF 1.53M

-34.8%

Short Term Debt

CHF 834.09K

-6.5%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-CHF 3.77M

+65.2%

Operating Cash Flow

-CHF 3.76M

+64.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VEXTFVext Science, Inc.
$0.18-6.77%
CVALFCovalon Technologies Ltd.
$1.54-0.65%
INNMFAmplia Therapeutics Limited
$0.08+0.00%
SEOVFSernova Corp.
$0.12-9.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.94+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$83.05+0.07%
SMCISuper Micro Computer
$30.33+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$36.73-0.07%

Questions About RLFTF

What is the current price of MindMaze Therapeutics?

MindMaze Therapeutics is trading at $0.29 per share.

What is the 52-week range for MindMaze Therapeutics?

Over the past 52 weeks, MindMaze Therapeutics has traded between $0.27 and $4.88.

How much debt does MindMaze Therapeutics have?

As of the most recent reporting period, MindMaze Therapeutics reported total debt of CHF 2.28M.

How much cash does MindMaze Therapeutics have on hand?

MindMaze Therapeutics reported CHF 11.96M in cash and cash equivalents in its most recent financial results.

What is MindMaze Therapeutics’s dividend yield?

MindMaze Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.